CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 9 enrolled
Drug / intervention
Pegylated Interferon Alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02829775
NCT02829775Phase 3Completed
CompareCT.gov

Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies

Hoffmann-La Roche·interventional·Posted Jul 12, 2016·Updated Jan 9, 2017

In Brief

A Phase 3 clinical trial evaluating Pegylated Interferon Alfa-2a and Recombinant Interferon Alfa 2a for Chronic Myelogenous Leukemia and 2 related conditions. Completed, enrolled 9 participants across 8 sites in 7 countries.

Detailed Summary

This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical studies NO15753 (NCT00003542) for Renal Cell Carcinoma (RCC), NO15764 (NCT number not available) and NO16006 (NCT02736721) for Chronic Myelogenous Leukemia (CML), and NO16007 (NCT number not available) for Malignant Melanoma (MM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
CountriesBulgaria, Canada, India, Russia, Slovakia, South Africa, Spain
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 12, 2016
Enrollment StartJan 1, 2004
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 10.0 years ago

Interventions

Pegylated Interferon Alfa-2adrug

Participants will maintain the same dose they were receiving in the parent protocol.

Recombinant Interferon Alfa 2adrug

Participants will maintain the same dose they were receiving in the parent protocol.